El informe publicado presenta un ranking con las 16 entidades españolas más destacadas en retorno económico en el que aparecen el IDIBAPS en cuarta posición con 3 proyectos financiados y la FCRB en novena posición con 4 proyectos financiados. Asimismo, los buenos resultados a nivel institucionales también se ven reflejados en la participación de los investigadores de la casa en los proyectos concedidos en la totalidad del programa de 2014-2015 del H2020:
|
Convocatoria |
Nombre del proyecto |
Investigador Principal |
Entidad |
|
Societal challenge 1: Personalising Health and Care |
|||
|
2014 |
Cost effective self-management of urinary incontinence addressed to women (WOMEN-UP) |
Dra. Montse Espuña |
FCRB |
|
2015 |
Development of a systems biomedicine approach for risk identification, prevention and treatment of type 2 diabetes (T2DSystems) |
Dr. Jorge Ferrer |
IDIBAPS |
|
2015 |
A EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA) |
Dr. Jose Maria Gatell |
IDIBAPS |
|
2014 |
Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease (CARBALIVE) |
Dr. Pere Ginès |
IDIBAPS |
|
2015 |
European AIDS Vaccine Initiative 2020 (EAVI2020) |
Dr. Joan Joseph |
FCRB |
|
2014 |
Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation (EmERGE) |
Dra. Agata León |
FCRB |
|
2015 |
Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities (HEP-CAR) |
Dr. Josep Maria Llovet |
IDIBAPS |
|
2014 |
Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly (CATCH ME) |
Dr. Lluís Mont |
IDIBAPS |
|
2014 |
Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performance (SELFIE) |
Dr. Josep Roca |
IDIBAPS |
|
2014 |
Aortic Valve Replacement using Individualised Regenerative Allografts: Bridging the Therapeutic Gap (ARISE) |
Dra. Marta Sitges |
IDIBAPS |
|
2014 |
Conservative iron chelation as a disease-modifying strategy in Parkinsons disease: a multicentric parallel-group,placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II) |
Dr. Eduardo Tolosa |
FCRB |
|
Excellent Science: Marie Sklodowska- Curie actions |
|||
|
Innovative Training Networks 2014 |
Computational and functional annotation of genomic elements during development of the model vertebrate zebrafish (ZENCODE) |
Dr. Jorge Ferrer |
IDIBAPS |
|
Individual Fellowships 2014 |
Analysis of tridimensional changes caused by type 2 Diabetes-Associated varianTs (3D-ADAPT) |
Dra. Irene Miguel-Escalada |
IDIBAPS |
|
Innovative Training Networks 2015 |
Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance (RELEVANCE) |
Dr. Joan Lluís VivesCorrons |
IDIBAPS |
|
Industrial Leadership: Leadership in Enabling and Industrial Technologies |
|||
|
ICT- 2015 |
Laser and Ultrasound Co-Analyzer for thyroid nodules (LUCA) |
Dr. Ramon Gomis |
IDIBAPS |
|
ICT- 2014 |
A Framework for user centred privacy and security in the cloud (CLARUS) |
Dr. David Vidal |
FCRB |
|
3rd Health Programme (CHAFEA) |
|||
|
2014 |
Stimulating Innovation Management of Polypharmacy and Adherence in The Elderly (SIMPATHY) |
Dr. Carles Codina |
FCRB |
|
ERA-NETS |
|||
|
EraCoSysMed2015 |
Personalizing health care in Multiple Sclerosis using systems medicine tolos (Sys4MS) |
Dr. Pablo Villoslada (Coordinator) |
IDIBAPS |
|
eRARE2015 |
A comprehensive clinical and experimental approach to personalized molecular medicine in patients with defined and undefined autoinflammatory disorders (INSAID) |
Dr. Juan Aróstegui |
FCRB |
|
TransCan2015 |
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemiaoutco resistance (GCH-CLL) |
Dr. Elias Campo |
FCRB |
|
InfectEra2015 |
SRCR proteins as microorganism pattern recognition receptors: a wide search for interactions with pathogenic bacteria (SRecognite) |
Dr. Francisco Lozano |
IDIBAPS |
|
NEURON 2014 |
Advancing an antigen-specific nanomedicine for the treatment of central nervous system autoimmunity (MS NANOMED) |
Dr. Pau Serra |
FCRB |
|
FET Flagships |
|||
|
Human Brain Project |
Slow Wave Dynamics: from experiments, analysis and models to rhythm restoration (SloW-Dyn) |
Dra. Maria Victoria Sánchez (Coordinator) |
IDIBAPS |
|
Human Brain Project |
WAVE SCALing Experiments and Simulations (WaveScalIES) |
Dra. Maria Victoria Sánchez |
IDIBAPS |
|
Graphene |
Graphene-based disruptive technologies (Graphenecore 1) |
Dra. Maria Victoria Sánchez |
IDIBAPS |
Además, el informe resalta que España se sitúa como el cuarto país en cuanto al retorno económico con un 9% detrás del Reino Unido (17,4%), Holanda (14,1%) y Alemania (13, 6%) y con una tasa de éxito del 10,7% en Europa (UE-28). La subvención total obtenida a nivel de todo el Estado es de 51,1 millones de euros.
Las instituciones y empresas españolas participan en 61 de las 114 actividades que han recibido financiación en el ámbito de la Salud, y de estas 61 lidera 17, de las que 15 son propuestas tipo Research and InnovationAction y Innovation Action.
Cabe destacar que los centros públicos de investigación ocupan el segundo lugar en cuanto a captación de estos recursos y que Cataluña es la comunidad autónoma que lidera el ranking español.
El análisis está basado en las primeras convocatorias abiertas dentro del nuevo programa marco[i]. Para más información, se puede consultar el informe del CDTI:
Participación española en Horizonte 2020: el programa marco de I+D+I de la UE (2014-2020)
[i] Convocatòries: H2020-PHC-2014-single-stage, H2020-HCO-2014, H2020-PHC-2014-2-stage i H2020-Adhoc-2014-20 Ebola.